Provided by Tiger Trade Technology Pte. Ltd.

Candel Therapeutics, Inc.

13.13
+0.78006.32%
Post-market: 13.10-0.0300-0.23%19:53 EDT
Volume:1.34M
Turnover:17.31M
Market Cap:1.00B
PE:-9.12
High:13.26
Open:12.52
Low:12.38
Close:12.35
52wk High:13.82
52wk Low:4.35
Shares:76.52M
Float Shares:60.06M
Volume Ratio:0.75
T/O Rate:2.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4390
EPS(LYR):-0.7210
ROE:-81.84%
ROA:-28.64%
PB:7.97
PE(LYR):-18.21

Loading ...

Candel Therapeutics Inc expected to post a loss of 32 cents a share - Earnings Preview

Reuters
·
May 08

Candel Therapeutics updates Phase 3 CAN-2409 data in localized prostate cancer trial

Reuters
·
May 04

Candel Therapeutics grants new-hire inducement options for 29,400 shares at $6.18 each

Reuters
·
May 02

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
May 02

Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer

GlobeNewswire
·
Apr 29

Candel Therapeutics Stock Soars After Cantor Fitzgerald's Overweight Rating

Benzinga_recent_news
·
Apr 21

Candel Therapeutics Initiated at Overweight by Cantor Fitzgerald

Dow Jones
·
Apr 20

Candel Therapeutics publishes corporate presentation on viral immunotherapies for solid tumors

Reuters
·
Apr 15

Candel Therapeutics grants 70,000 inducement stock options to five new employees

Reuters
·
Apr 03

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Apr 03

Insider Purchases Worth US$3.00m See Losses As Candel Therapeutics Market Value Drops To US$352m

Simply Wall St.
·
Mar 31

Candel Therapeutics Is Maintained at Buy by Citigroup

Dow Jones
·
Mar 18

Candel Therapeutics Inc : Citigroup Raises Target Price to $26 From $22

THOMSON REUTERS
·
Mar 18

U.S. RESEARCH ROUNDUP-Factset, Lensar, Starbucks

Reuters
·
Mar 18

CAN-2409’s Emerging Survival Benefit and Biomarker-Driven Immunotherapy Platform Support Buy Rating and $23 Target

TIPRANKS
·
Mar 17

Candel Therapeutics publishes corporate presentation on its viral immunotherapy cancer pipeline

Reuters
·
Mar 17

BRIEF-Candel Therapeutics Inc Extended Survival Tail Observed In Trial Of Aglatimagene Besadenovec

Reuters
·
Mar 17

Candel Therapeutics Inc: Phase 3 Pivotal Study Planned for Initiation in Q2 2026

THOMSON REUTERS
·
Mar 17

Candel Therapeutics Inc: Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec

THOMSON REUTERS
·
Mar 17

Candel Therapeutics reports 25.4-month median overall survival and 50% 24-month survival in CAN-2409 phase 2a NSCLC trial

Reuters
·
Mar 17